Childhood medulloblastoma. (September 2016)

• Record Type: Journal Article
• Authors: Massimino, Maura; Biassoni, Veronica; Gandola, Lorenza; Garrè, Maria Luisa; Gatta, Gemma; Giangaspero, Felice; Poggi, Geraldina; Rutkowski, Stefan
• Is Part Of: Critical reviews in oncology/hematology. Volume 105(2016)
• Page Start: 35
• Page End: 51
• Publication Date: 2016-09
• Subjects: Medulloblastoma -- Pediatric brain tumours -- Prognosis -- Target therapy -- Molecular subgroups -- Rehabilitation in brain tumours; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2016.05.012
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Medulloblastoma accounts for 15–20% of childhood nervous system tumours. The risk of dying was reduced by 30% in the last twenty years. Patients are divided in risk strata according to post-surgical disease, dissemination, histology and some molecular features such as WNT subgroup and MYC status. Sixty to 70% of patients older than 3 years are assigned to the average-risk group. High-risk patients include those with disseminated and/or residual disease, large cell and/or anaplastic histotypes, MYC genes amplification. Current and currently planned clinical trials will: (1) evaluate the feasibility of reducing both the dose of craniospinal irradiation and the volume of the posterior fossa radiotherapy (RT) for those patients at low biologic risk, commonly identified as those having a medulloblastoma of the WNT subgroup; (2) determine whether intensification of chemotherapy (CT) or irradiation can improve outcome in patients with high-risk disease; (3) find target therapies allowing tailored therapies especially for relapsing patients and those with higher biological risk.